XVIVO Presents Report on Operations 2023
GOTHENBURG, SWEDEN / ACCESSWIRE / January 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Fourth quarter 2023 (October 1 - December 31) • Net sales amounted to SEK 155.7 million (131....
- Supported exchanges /
- LSE /
- 0RKL.LSE
Xvivo Perfusion AB (0RKL LSE) stock market data APIs
kr508
-1(-0.2%)
as of September 17, 2024
Price chart is built with Anychart
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.
Xvivo Perfusion AB Financial Data Overview
| 509 | |
| 508 | |
| - | |
| 510 | |
| 507 | |
| 205.5-545 | |
| 13 485 M | |
| 21.4767 | |
| 26 403 K | |
| 699 M | |
| 0.8601 | |
| 2.097 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'0RKL',
Type:
'Common Stock',
Name:
'Xvivo Perfusion AB',
Exchange:
'LSE',
CurrencyCode:
'SEK',
CurrencyName:
'Swedish krone',
CurrencySymbol:
'kr',
CountryName:
'UK',
CountryISO:
'GB',
OpenFigi:
NULL,
ISIN:
NULL,
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'',
Industry:
'',
}
Xvivo Perfusion AB Fundamental Data is available in our Financial Data APIs
- Net Revenue 699 M
- EBITDA 64 860 K
- Earnings Per Share 0.237
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Xvivo Perfusion AB Earnings via APIs
- Latest Release 2024-07-12
- EPS/Forecast NaN
Get Xvivo Perfusion AB End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Xvivo Perfusion AB latest news via APIs
Extended Perfusion Time of Livers Can Streamline Planning and Logistics - Enabling More Liver Transplants to be Performed During Daytime
GOTHENBURG, SE / ACCESSWIRE / January 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) In a recently published [1] clinical trial conducted by the UMCG in Groningen, the Netherlands, XVIV...
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
